Abstract:See Josephs (doi:10.1093/brain/awx367) for a scientific commentary on this article.In many neurodegenerative disorders, familial forms have provided important insights into the pathogenesis of their corresponding sporadic forms. The first mutations associated with frontotemporal lobar degeneration (FTLD) were found in the microtubule-associated protein tau (MAPT) gene on chromosome 17 in families with frontotemporal degeneration and parkinsonism (FTDP-17). However, it was soon discovered that 50% of these families had a nearby mutation in progranulin. Regardless, the original FTDP-17 nomenclature has been retained for patients with MAPT mutations, with such patients currently classified independently from the different sporadic forms of FTLD with tau-immunoreactive inclusions (FTLD-tau). The separate classification of familial FTLD with MAPT mutations implies that familial forms cannot inform on the pathogenesis of the different sporadic forms of FTLD-tau. To test this assumption, this study pathologically assessed all FTLD-tau cases with a known MAPT mutation held by the Sydney and Cambridge Brain Banks, and compared them to four cases of four subtypes of sporadic FTLD-tau, in addition to published case reports. Ten FTLD-tau cases with a MAPT mutation (K257T, S305S, P301L, IVS10+16, R406W) were screened for the core differentiating neuropathological features used to diagnose the different sporadic FTLD-tau subtypes to determine whether the categorical separation of MAPT mutations from sporadic FTLD-tau is valid. Compared with sporadic cases, FTLD-tau cases with MAPT mutations had similar mean disease duration but were younger at age of symptom onset (55 ± 4 years versus 70 ± 6 years). Interestingly, FTLD-tau cases with MAPT mutations had similar patterns and severity of neuropathological features to sporadic FTLD-tau subtypes and could be classified into: Pick's disease (K257T), corticobasal degeneration (S305S, IVS10‰+‰16, R406W), progressive supranuclear palsy (S305S) or globular glial tauopathy (P301L, IVS10‰+‰16). The finding that the S305S mutation could be classified into two tauopathies suggests additional modifying factors. Assessment of our cases and previous reports suggests that distinct MAPT mutations result in particular FTLD-tau subtypes, supporting the concept that they are likely to inform on the varied cellular mechanisms involved in distinctive forms of sporadic FTLD-tau. As such, FTLD-tau cases with MAPT mutations should be considered familial forms of FTLD-tau subtypes rather than a separate FTDP-17 category, and continued research on the effects of different mutations more focused on modelling their impact to produce the very different sporadic FTLD-tau pathologies in animal and cellular models.

P3‐148: Brain Hypometabolism and Decreased Dopamine Transporter Distribution in Asymptomatic MAPT N279K Mutation Carriers in Familial FTDP‐17 Pedigree from China

Clinical and Pathological Features of FTDP-17 with MAPT p.K298_H299insQ Mutation

Reconfigured metabolism brain network in asymptomatic microtubule-associated protein tau mutation carriers: a graph theoretical analysis

ACCELERATED NEUROCHEMICAL CHANGES PRIOR TO PHENOCONVERSION TO FRONTOTEMPORAL LOBAR DEGENERATION IN PRESYMPTOMATIC MICROTUBULE-ASSOCIATED PROTEIN TAU (MAPT) MUTATION CARRIERS: A LONGITUDINAL MRS STUDY

P2-329: TRACKING WHITE MATTER DEGENERATION IN ASYMPTOMATIC AND SYMPTOMATIC MAPT MUTATION CARRIERS WITH DTI

In Vivo 18 F‐APN ‐1607 Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross‐Sectional and Longitudinal Findings

A Peculiar Tau Accumulation Pattern Identified Via 18 F-Florzolotau PET Imaging in a Patient With Frontotemporal Dementia Caused by a Mutation in the MAPT Gene

In Vivo18F‐APN‐1607 Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross‐Sectional and Longitudinal Findings

Imaging Biomarkers for Neurodegeneration in Presymptomatic Familial Frontotemporal Lobar Degeneration

A Case of Early-Onset Alzheimer's Disease with MAPT P301L Mutation and Literature Review

Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies

Brain volumetric deficits in MAPT mutation carriers: a multisite study

Neuroimaging and Neuropsychological Findings in MAPT N279K Mutation Phenoconverters

Neurite-based white matter alterations in MAPT mutation carriers: A multi-shell diffusion MRI study in the ALLFTD consortium

Rates of Lobar Atrophy in Asymptomatic MAPT Mutation Carriers

A Longitudinal 18F‐FDG PET Study in Asymptomatic Stage of Genetic Creutzfeldt–Jakob Disease

[P3–364]: ACCELERATED SUBCORTICAL ATROPHY DURING AGING IN PRESYMPTOMATIC CARRIERS OF C9ORF72 MUTATION

Clinical Features and Biomarkers of Semantic Variant Primary Progressive Aphasia with MAPT Mutation

Molecular imaging biomarkers in familial frontotemporal lobar degeneration: Progress and prospects

Tracking White Matter Degeneration in Asymptomatic and Symptomatic MAPT Mutation Carriers.

18F-APN-1607 Tau PET in Progressive Supranuclear Palsy-Like Symptoms Caused by TBK1 Mutations